Retatrutide is a new medication that shows great promise in the treatment of diabetes and obesity. Also referred to as GLP-1/GIP/glucagon tri-agonist or GGG Tri-agonist, this is peptide is more effective than semaglutide and tirzepatide, two popular weight-loss peptides. Retatrutide has the potential to enhance weight reduction outcomes and manage obesity-related comorbidities like diabetes and hypertension (high blood pressure) when paired with a healthy diet, consistent exercise, and lifestyle adjustments.